It’s no secret that physicians are the interface between device makers and the patient, but their role in cybersecurity has been limited to date. However, Christian Dameff, assistant professor of biomedical informatics and computer science at the University of California San Diego, said its time to engage physicians once they are in practice and to include cybersecurity in medical school education, two efforts he said would go a long way toward improving medical device cybersecurity in the clinical setting.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Applied DNA, Bioecho Life Sciences, Desktop Health, Chordate Medical, Endologix, Johnson & Johnson Vision, Qiagen.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Burning Rock Biotech, Cyduct Diagnostics, E Ink, Ers Genomics, Flagship Biosciences, Fluorogenics, Fujifilm, Galaxy Medical, Genscript Biotech, Helio Health, Hhc Preferred, Japan Lifeline, Leap Therapeutics, Lucira, New England Biolabs, Novartis, Nuclera Nucleic, Pmb-Alcen, Sagentia Innovation, Sientra, Tilak Healthcare, Wearable Health Solutions.
Med-tech firms raising money in public or private financings, including: Axonics, Bluestar Genomics, Dr First, Juno Diagnostics, Mindera, Treatment.com International.
Multinational players are changing the way they look at China as a source for innovation as it accelerates efforts in areas such as digital health in pursuit of desire to make a global impact. At the Chinabio Partnering Forum, panelists representing Pfizer Inc., Merck & Co. Inc., Sanofi SA and Johnson & Johnson all shared what they have witnessed there and how they’re already tapping China-sourced innovations.
PERTH, Australia – Australia’s budget theme for the 2021 to 2022 fiscal year is rebuilding the economy following COVID-19, and med-tech and biotech leaders were praising some of the new measures.
Avenda Health Inc. has taken a page out of the breast cancer book with a new technology that offers very localized treatment of prostate tumors in a procedure the company refers to as a prostate cancer lumpectomy. The FDA granted breakthrough device designation to the product based on its potential to transform care for one of the most common cancers.
The controversy over the use of ethylene oxide (EtO) is back in play, thanks to a May 5 letter from the Office of Inspector General at the Environmental Protection Agency to the EPA. The letter recommends that the agency revisit its work on determining the status of EtO based on new data, data that may lead to more restricted use of EtO to sterilize medical devices.
RSS
